Muscarinic receptor activation modulates the excitability of hilar mossy cells through the induction of an afterdepolarization.
In the present study we used electrophysiological techniques in an in vitro preparation of the rat dentate gyrus to examine the effect of muscarinic acetylcholine receptor activation on the intrinsic excitability of hilar neurons. We found that bath application of muscarine caused a direct depolarization in approximately 80% of mossy cells tested, and also produced a clear afterdepolarization (ADP) in nearly 100% of trials. The ADP observed in hilar mossy cells is produced by the opening of a Na(+) permeant and yet largely TTX insensitive ion channel. It requires an increase in postsynaptic calcium for activation, and is blocked by flufenamic acid, an antagonist of a previously identified calcium activated non-selective cation channel (I(CAN)). Further, we demonstrate that induction of an ADP in current clamp causes release of cannabinoids, and subsequent depression of GABAergic transmission that is comparable to that produced in the same cells by a more conventional 5s depolarization in voltage clamp. By contrast, other types of hilar neurons were less strongly depolarized by bath application of muscarinic agonists, and uniformly lacked a similar muscarinic ADP. Overall, the data presented here extend our understanding of the specific mechanisms through which muscarinic agonists are likely to modulate neuronal excitability in the hilar network, and further reveal a mechanism that could plausibly promote endocannabinoid mediated signaling in vivo.
Hofmann
Mackenzie E
ME
Department of Pharmacodynamics, College of Pharmacy, University of Florida, USA; Department of Neuroscience, College of Medicine, University of Florida, USA.
Frazier
Charles J
CJ
D000818:Animals; D002118:Calcium / Q000378:metabolism; D063385:Cannabinoid Receptor Modulators / Q000378:metabolism; D002491:Central Nervous System Agents / Q000494:pharmacology; D018891:Dentate Gyrus / Q000187:drug effects / Q000502:physiology; D005439:Flufenamic Acid / Q000494:pharmacology; D066298:In Vitro Techniques; D007473:Ion Channels / Q000037:antagonists & inhibitors / Q000378:metabolism; D008297:Male; D008564:Membrane Potentials / Q000187:drug effects / Q000502:physiology*; D019599:Mossy Fibers, Hippocampal / Q000187:drug effects / Q000502:physiology*; D009116:Muscarine / Q000378:metabolism; D009474:Neurons / Q000187:drug effects / Q000502:physiology; D051381:Rats; D017207:Rats, Sprague-Dawley; D011976:Receptors, Muscarinic / Q000378:metabolism*; D015222:Sodium Channels / Q000378:metabolism; D009435:Synaptic Transmission / Q000187:drug effects / Q000502:physiology; D005680:gamma-Aminobutyric Acid / Q000378:metabolism
D063385:Cannabinoid Receptor Modulators; D002491:Central Nervous System Agents; D007473:Ion Channels; D011976:Receptors, Muscarinic; D015222:Sodium Channels; D005680:gamma-Aminobutyric Acid; D005439:Flufenamic Acid; D009116:Muscarine; D002118:Calcium